Science AI Journal
Medicine · Research topic

Open research questions in Cardiomyopathy and Myosin Studies

113 unresolved questions extracted from the limitations and future-work sections of 339 Cardiomyopathy and Myosin Studies papers in our library. Each links back to the study that raised it.

What the literature leaves open

  • Further studies are needed to clarify the biological mechanisms of FLNC-related cardiac disease - Investigation of the correlation between LVEF and arrhythmic risk is necessary - Research on the clinical management of patients with FLNC variants is required

    The Multifaceted Role of the FLNC Gene in Hereditary Cardiomyopathies and Prognosis · 2026 · DOI

  • There is a need for accurate variant classification and phenotype integration to diagnose and prevent sudden cardiac death. The clinical interpretation of FLNC variants depends strongly on variant class and evidence of pathogenicity.

    The Multifaceted Role of the FLNC Gene in Hereditary Cardiomyopathies and Prognosis · 2026 · DOI

  • The relationship between atrial remodelling and disease progression in HCM is not fully understood. The prognostic role and therapeutic target of atrial remodelling in HCM are not well established. There is a need for further research on the effects of therapeutic interventions on atrial remodelling in HCM patients.

    Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target · 2025 · DOI

  • Muscle function depends on the ability of myofibrils to withstand and repair mechanical damage, yet how adult muscles remodel damaged myofibrils remains poorly understood.

    Evidence of complete myofibril remodeling after severe damage in adult Drosophila. · 2026 · DOI

  • Both myotropes bind to the same myosin pocket but their mechanisms of action remain incompletely understood.

    Myotropes unveil two myosin cycles with distinct kinetics and stroke size · 2026 · DOI

  • Percutaneous intramyocardial septal radiofrequency ablation (Liwen procedure) is a less invasive alternative, but head-to-head comparisons of longitudinal hemodynamic trajectories and conduction system safety remain scarce, limiting evidence-based treatment selection.

    Liwen Ablation versus Modified Morrow Myectomy for Obstructive Hypertrophic Cardiomyopathy: 1-Year Hemodynamic and Conduction Outcomes · 2026 · DOI

  • Background: Hypertrophic cardiomyopathy (HCM) exhibits clinical heterogeneity and age-related penetrance, yet its molecular basis across adulthood remains incompletely understood.

    Age-Stratified Integrative Transcriptomic Analysis Reveals a Conserved Fibrotic Core and Distinct Molecular Signatures in Hypertrophic Cardiomyopathy · 2026 · DOI

  • Emerging therapies, like cardiac myosin inhibitors, also improve LV function but present complex effects on atrial performance, with some evidence suggesting a reduction in atrial strain that warrants further investigation.

    Atrial remodelling and dysfunction in hypertrophic cardiomyopathy: prognostic role and therapeutic target · 2025 · DOI

  • The natural history of MFM and myopathies associated with MFM-related genes remains poorly characterized.

    Natural History and Phenotypic Spectrum of Myofibrillar Myopathies and Myopathies Associated With MFM-Related Genes · 2025 · DOI

  • How these three proteins interact to control thick filament activation is poorly understood.

    Structure of mavacamten-free human cardiac thick filaments within the sarcomere by cryoelectron tomography · 2024 · DOI

  • Although recommended in current guidelines, data on the direct effect of discontinuing afterload-reducing medication are scarce.

    Discontinuation of afterload-reducing drugs decreases left ventricular outflow tract obstruction in hypertrophic obstructive cardiomyopathy · 2024 · DOI

  • However, the exact prevalence of PH in ApHCM and sex differences remain uncertain.

    Prevalence, sex differences, and implications of pulmonary hypertension in patients with apical hypertrophic cardiomyopathy · 2024 · DOI

  • Background While electrocardiographic parameters of hypertensive left ventricular hypertrophy (H-LVH) are well known, limited data are available regarding hypertrophic cardiomyopathy (HCM).

    Clinical utility of electrocardiographic voltage parameters for the diagnosis of hypertrophic cardiomyopathy · 2024 · DOI

  • Consequently, evidence for guideline recommendations in this patient population is lacking.

    No beneficial use of the wearable cardioverter defibrillator among patients suffering from inherited and congenital heart disease: data from a European multicenter registry · 2024 · DOI

  • Abstract Familial cardiomyopathy in pediatric stages is a poorly understood presentation of heart disease in children that is attributed to pathogenic mutations.

    Recessive TMOD1 mutation causes childhood cardiomyopathy · 2024 · DOI

  • Genetic myopathies are frequently involved; however, studies using next-generation sequencing (NGS) in pediatric patients are lacking, and the significance of genetic aberrations remains poorly understood.

    Asymptomatic HyperCKemia in the Pediatric Population · 2024 · DOI

  • The primary limitation of this study was that not all ancillary tests were performed in all recruited patients owing to ethical restrictions, which lowered the power of the predictive analysis.

    Asymptomatic HyperCKemia in the Pediatric Population · 2024 · DOI

  • Unlike adult DCM, the pathogenesis of pediatric DCM is not well understood as approximately two thirds of cases are classified as idiopathic disease.

    Pediatric dilated cardiomyopathy: a review of current clinical approaches and pathogenesis · 2024 · DOI

  • The developmental mechanism underpinning noncompaction in the adult heart is still not fully understood, with lack of trabeculae compaction, hypertrabeculation, and loss of proliferation cited as possible causes.

    Morphological, electrophysiological, and molecular alterations in foetal noncompacted cardiomyopathy induced by disruption of ROCK signalling · 2024 · DOI

  • The study has a small sample size of 10 neonates. The follow-up period was limited to 1 year.

    Clinical characteristics and short-term outcomes of left ventricular non-compaction cardiomyopathy in neonates · 2026 · DOI

  • The diagnosis of LVNC is challenging due to its highly variable clinical manifestations. There is a need for studies on the clinical characteristics and short-term outcomes of LVNC in neonates.

    Clinical characteristics and short-term outcomes of left ventricular non-compaction cardiomyopathy in neonates · 2026 · DOI

  • The mechanical properties of MYO1B and its role in cellular processes are not well understood. The regulation of MYO1B and its implications for human diseases are not well studied.

    MYO1B in human disease: an actin-based motor linking membrane trafficking to oncogenic signaling, metastasis, and vascular aging · 2026 · DOI

  • There is a paucity of literature on mid-ventricular obstruction. The use of mavacamten in patients with mid-ventricular and apical hypertrophic cardiomyopathy has not been well-studied.

    Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction · 2026 · DOI

  • This is a single case report; controlled trials with larger patient populations are needed to establish the efficacy and safety of mavacamten specifically in MVO and apical HCM phenotypes.

    Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction · 2026 · DOI

  • To investigate the prognostic value of T1ρ mapping. To compare T1ρ mapping with other non-contrast CMR techniques. To evaluate the performance of T1ρ mapping in a larger cohort of patients.

    Assessment of myocardial fibrosis in ischemic and non-ischemic cardiomyopathies using cardiac magnetic resoance non-contrast T1ρ mapping · 2026 · DOI

Most-cited papers in Cardiomyopathy and Myosin Studies

Most recent work

Find a gap in your own Cardiomyopathy and Myosin Studies sub-topic

This page shows what the Cardiomyopathy and Myosin Studies literature already flags as unresolved. To narrow it to your specific question, run the guided finder — it searches the gap library on demand and checks candidates against 250M+ OpenAlex works.

Open the Research Gap Finder →

Related topics in Medicine

Artificial Intelligence in Healthcare and Education
2,044 open questions
Substance Abuse Treatment and Outcomes
1,964 open questions
Smoking Behavior and Cessation
990 open questions
Dementia and Cognitive Impairment Research
974 open questions
Innovations in Medical Education
960 open questions
Physical Activity and Health
923 open questions
Attention Deficit Hyperactivity Disorder
839 open questions
Schizophrenia research and treatment
709 open questions
113 open questions have been extracted from the limitations and future-work passages of 339 Cardiomyopathy and Myosin Studies papers in our library. Each one below links back to the study that raised it, so you can read the original claim in context.

Tools for your next paper

Gaps & Literature SearchFind open questions in any field — 120,000+ open gaps mined from our own library.Pre-CheckIs your paper ready? A Tier 1–5 acceptance probability in seconds.Journal FinderA ranked shortlist of target journals from a 17,500-venue index.Duplicate Publication CheckerCheck prior-publication & salami-slicing risk across 8 sources.Citation GeneratorFreeA DOI or title → APA, MLA, Vancouver, Chicago, BibTeX, RIS. No signup.Graphical Abstract MakerFreeTurn your findings into a colorblind-safe graphical abstract.

Compare the category — Honest roundups of the AI research tools, ours listed alongside the alternatives.

Command palette

Jump anywhere, run any action.